Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same

Abstract

This disclosure relates to compounds selected from Formula 1, enantiomers, diastereomers, solvates, hydrates, or pharmaceutically acceptable salts thereof, methods of their preparation, and their uses. The present disclosure relates to a compound selected from a compound of Formula 1, an enantiomer, diastereomer, solvate, hydrate, or pharmaceutically acceptable salt thereof, methods of preparing the same, and uses thereof.